Fintel reports that on January 27, 2025, Morgan Stanley downgraded their outlook for Intellia Therapeutics (NasdaqGM:NTLA) from Overweight to Equal-Weight. Analyst Price Forecast Suggests 449.14% ...

Intellia Therapeutics (NASDAQ:NTLA) announces that China’s State Intellectual Property Office will grant a patent covering CRISPR/Cas9 single-guide gene editing ...

CARGO Therapeutics, Inc. (CRGX – Research Report) received a Hold rating and price target from Chardan Capital analyst Geulah Livshits ...

Intellia Therapeutics has said it will reduce its ... its resources behind two priority drug candidates. The specialist in CRISPR-based gene editing – co-founded by Nobel Prize winner Jennifer ...

CRISPR Therapeutics already has financial backing from Celgene and in October announced a discovery alliance with Vertex in cystic fibrosis. Novartis has a stake in rivals Intellia Therapeutics ...

Intellia Therapeutics is developing novel, potentially curative therapeutics leveraging CRISPR-based technologies. Our in vivo programs use IV-administered CRISPR as the therapy, in which proprietary ...

CRISPR Therapeutics AG has a 1 year low of $36.52 and a 1 year high of $91.10. CRISPR Therapeutics (NASDAQ:CRSP – Get Free Report) last released its quarterly earnings data on Tuesday, November 5th.

ZUG, Switzerland and BOSTON, Jan. 29, 2025 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious ...